Compound profile
FOXO4-DRI
EmergingAlso known as: FOXO4 D-retro-inverso peptide · senolytic peptide
A lab-designed "D-retro-inverso" peptide built to disrupt one specific protein-protein interaction that keeps aged cells alive, making it a purpose-built senolytic rather than a naturally occurring hormone fragment. Widely cited in longevity media as the "reverse aging in mice" peptide.
Overview
FOXO4-DRI is not a peptide the body makes or a fragment pulled from a natural hormone. It is a purpose-built laboratory tool, designed from the ground up to interfere with one specific interaction between two proteins inside a particular kind of cell: senescent cells, sometimes informally called zombie cells, which are cells that have stopped dividing but refuse to die and instead linger in tissue, secreting inflammatory signals that are thought to contribute to aging and age-related disease.
The peptide was developed by Peter de Keizer and colleagues at Erasmus University Medical Center in Rotterdam and described in a widely covered 2017 paper in the journal Cell. It uses a design approach called D-retro-inverso, where the peptide's amino acid sequence is reversed and built entirely from mirror-image D-amino acids rather than the L-amino acids that make up natural proteins. That construction makes the peptide much more resistant to being broken down by the body's normal peptide-degrading enzymes while still fitting into the same binding pocket as the natural target sequence.
FOXO4-DRI became widely cited in longevity media after the 2017 paper reported striking results in aged mice, often summarized in headlines as reversing aging. That framing runs well ahead of where the science actually stands: all of the efficacy data for FOXO4-DRI exists in cell culture and mouse studies, and no human trial, human dosing data, or human safety data exists for this compound.
Mechanism (plain language)
Competes with the transcription factor FOXO4 for binding to p53 inside senescent cells, which pushes p53 out of the nucleus and triggers apoptosis selectively in senescent (not healthy) cells in the foundational cell-biology work.
How it works
Senescent cells survive, despite having stopped dividing, partly because a protein called FOXO4 binds to and holds onto p53, a well-known tumor-suppressor protein that would otherwise push a damaged or stressed cell toward apoptosis, a controlled form of cell death. By keeping p53 sequestered this way, FOXO4 effectively helps senescent cells evade the death signal they would normally receive, allowing them to persist in tissue and continue secreting inflammatory molecules as part of what researchers call the senescence-associated secretory phenotype.
FOXO4-DRI works by competing with the natural FOXO4 protein for that same binding site on p53. Because FOXO4-DRI is built to mimic the relevant part of FOXO4's structure, it can displace the real FOXO4 protein from p53, which frees p53 to move out of the nucleus and trigger apoptosis, but according to the foundational research, this happens selectively in senescent cells rather than in healthy, still-dividing ones. In the original mouse studies, that selective clearance of senescent cells was associated with improvements in several markers of physical decline, including fur density, kidney function, and general activity levels, without apparent harm to healthy tissue at the doses tested.
What research suggests
The foundational study reported that FOXO4-DRI selectively killed senescent cells in vitro and, in naturally aged and fast-aging mice, restored fitness, fur density, and renal function without effects on healthy tissue at the doses tested.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Selective killing of senescent cells
The foundational 2017 study reported that FOXO4-DRI selectively induced cell death in senescent cells in laboratory (in vitro) models, while sparing healthy, non-senescent cells.
Restored physical fitness markers in aged mice
Naturally aged mice treated with FOXO4-DRI showed improvements in activity levels and general fitness measures compared with untreated controls.
Improved fur density in mouse models
Treated mice showed increased fur density, a commonly used visible marker of biological aging in mouse studies.
Improved kidney function in mouse models
The same study reported improved renal function in treated aged mice.
Protection against fast-aging phenotypes
In mouse models bred to age rapidly (progeria-like models), FOXO4-DRI treatment was reported to counter some of the accelerated aging features.
Uncertainties & risks
All efficacy data is in mice and cell culture; there are no published human trials, doses, or safety data. "Reverses aging in mice" headlines substantially outrun what has been shown in people, and D-retro-inverso peptides in general have limited precedent in approved human therapeutics.
The single most important thing to understand about FOXO4-DRI is that every piece of efficacy evidence for it comes from cell culture experiments and mouse studies. There is no published human trial, no established human dose, and no human safety data of any kind. The gap between reversing aging in mice media coverage and what has actually been demonstrated in people is about as large as it gets among the peptides discussed on this site. D-retro-inverso peptides as a design category also have limited precedent in approved human therapeutics generally, meaning even the broader engineering approach behind FOXO4-DRI has not been extensively validated in human drug development the way that, for example, standard peptide hormone analogues have. Mouse senescence models, while useful for generating hypotheses, are also known to translate imperfectly to human aging biology, which is a complex, multi-system process that a single mouse study cannot fully capture. Anyone encountering FOXO4-DRI as a research chemical should treat it as an interesting, mechanistically specific laboratory tool at a very early stage, not as a tested or safety-characterized human intervention.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.